ALT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Altimmune Inc (ALT) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows positive momentum, insider buying activity, strong analyst support with high price targets, and promising financial growth trends. Despite some financial losses, the company's lead asset has significant potential, making it a suitable long-term investment.
The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 70.284, and the stock is trading near its resistance level of 3.506, suggesting potential for further upward movement. Moving averages are converging, which does not indicate a clear trend reversal.
Insider buying: John Gill purchased 9,200 shares recently, signaling confidence in the company's future.
Analyst ratings are overwhelmingly positive, with multiple Buy ratings and price targets ranging from $7 to $
The company's lead asset, pemvidutide, has strong potential in treating MASH and alcohol-related liver diseases, supported by promising clinical data.
Revenue growth of 420% YoY in Q4 2025 highlights strong operational performance.
The company reported a net loss of $27.36M in Q4 2025, though it improved YoY.
EPS dropped by 21.21% YoY, which may concern some investors.
No recent trading activity from hedge funds or Congress, indicating a lack of broader institutional interest.
In Q4 2025, Altimmune reported a 420% YoY revenue increase to $26,000, indicating strong growth. However, the company posted a net loss of $27.36M, though this was an 18.02% improvement YoY. EPS dropped by 21.21% YoY to -0.26, while gross margin remained stable at 100%.
Analysts are highly optimistic about Altimmune, with multiple Buy ratings and price targets ranging from $7 to $25. Key drivers include the potential of pemvidutide in treating MASH and alcohol-related liver diseases, as well as a strong financial runway and near-term catalysts such as Phase 2 and Phase 3 clinical data.
